378 related articles for article (PubMed ID: 28303632)
1. The comparative safety and effectiveness of bivalirudin versus heparin monotherapy in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan cardiovascular consortium.
Sukul D; Seth M; Schreiber T; Khandelwal A; Cannon LA; LaLonde TA; Gurm HS
Catheter Cardiovasc Interv; 2017 Nov; 90(5):724-732. PubMed ID: 28303632
[TBL] [Abstract][Full Text] [Related]
2. Impact of worsening renal dysfunction on the comparative efficacy of bivalirudin and platelet glycoprotein IIb/IIIa inhibitors: insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium.
Perdoncin E; Zhang M; Riba A; LaLonde TA; Grines CL; Gurm HS
Circ Cardiovasc Interv; 2013 Dec; 6(6):688-93. PubMed ID: 24280966
[TBL] [Abstract][Full Text] [Related]
3. Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States.
Secemsky EA; Kirtane A; Bangalore S; Jovin IS; Shah RM; Ferro EG; Wimmer NJ; Roe M; Dai D; Mauri L; Yeh RW
JACC Cardiovasc Interv; 2016 Dec; 9(23):2376-2386. PubMed ID: 27838271
[TBL] [Abstract][Full Text] [Related]
4. Comparison of heparin and bivalirudin in patients undergoing percutaneous coronary intervention without use of glycoprotein IIb/IIIa inhibitors.
Abtahian F; Waldo S; Jang IK
Catheter Cardiovasc Interv; 2015 Sep; 86(3):390-6. PubMed ID: 25753749
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulant Use Among Patients With End-Stage Renal Disease Undergoing Percutaneous Coronary Intervention: An Analysis From the National Cardiovascular Data Registry.
Washam JB; Kaltenbach LA; Wojdyla DM; Patel MR; Klein AJ; Abbott JD; Rao SV
Circ Cardiovasc Interv; 2018 Feb; 11(2):e005628. PubMed ID: 29432119
[TBL] [Abstract][Full Text] [Related]
6. Gender-based outcomes of bivalirudin versus heparin in patients undergoing percutaneous coronary interventions: Meta-analysis of randomized controlled trials.
Mina GS; Firouzbakht T; Modi K; Dominic P
Catheter Cardiovasc Interv; 2017 Nov; 90(5):735-742. PubMed ID: 28339139
[TBL] [Abstract][Full Text] [Related]
7. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.
Hibbert B; MacDougall A; Labinaz M; O'Brien ER; So DY; Dick A; Glover C; Froeschl M; Marquis JF; Wells GA; Blondeau M; Le May MR
Circ Cardiovasc Interv; 2012 Dec; 5(6):805-12. PubMed ID: 23149331
[TBL] [Abstract][Full Text] [Related]
8. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
[TBL] [Abstract][Full Text] [Related]
9. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice.
Zhang Y; Zhang Y; Liu Z; Zhang B; Liu G; Chen K
Biomed Pharmacother; 2020 Oct; 130():110758. PubMed ID: 34321166
[TBL] [Abstract][Full Text] [Related]
10. Heparin versus bivalirudin for non-primary percutaneous coronary intervention: A post-Hoc analysis of the CPORT-E trial.
Czarny MJ; Hwang CW; Naiman DQ; Lemmon CC; Hasan RK; Wang T; Aversano T
Catheter Cardiovasc Interv; 2017 Sep; 90(3):366-377. PubMed ID: 28160375
[TBL] [Abstract][Full Text] [Related]
11. Bivalirudin in percutaneous coronary intervention for chronic total occlusion: A single-center pilot study.
Li C; Xu R; Shen Y; Dai Y; Zhang F; Ma J; Ge L; Qian J; Ge J
Catheter Cardiovasc Interv; 2018 Mar; 91(4):679-685. PubMed ID: 28766879
[TBL] [Abstract][Full Text] [Related]
12. Temporal trends, safety, and efficacy of bivalirudin in elective percutaneous coronary intervention: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium.
Gurm HS; Smith DE; Chetcuti SJ; Share D; Khanal S; Riba A; Carter AJ; Lalonde T; Kline-Rogers E; O'Donnell M; O'Neill W; Safian R; Moscucci M;
J Interv Cardiol; 2007 Jun; 20(3):197-203. PubMed ID: 17524111
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice.
Kim LK; Wong SC; Minutello RM; Bergman G; Feldman DN
J Invasive Cardiol; 2010 Mar; 22(3):94-100. PubMed ID: 20197573
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
[TBL] [Abstract][Full Text] [Related]
15. Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin Versus Heparin: A Report From the National Cardiovascular Data Registry.
Jovin IS; Shah RM; Patel DB; Rao SV; Baklanov DV; Moussa I; Kennedy KF; Secemsky EA; Yeh RW; Kontos MC; Vetrovec GW
JACC Cardiovasc Interv; 2017 Jun; 10(11):1102-1111. PubMed ID: 28527778
[TBL] [Abstract][Full Text] [Related]
16. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III).
Waksman R; Bertrand O; Driesman M; Gruberg L; Rossi J; Mehta S; Swymelar S; Dvir D; Xue Z; Torguson R
J Interv Cardiol; 2013 Apr; 26(2):107-13. PubMed ID: 23240743
[TBL] [Abstract][Full Text] [Related]
17. Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry.
Bangalore S; Pencina MJ; Kleiman NS; Cohen DJ
Circ Cardiovasc Interv; 2014 Jun; 7(3):365-73. PubMed ID: 24736878
[TBL] [Abstract][Full Text] [Related]
18. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris.
Steinberg DH; Shah P; Kinnaird T; Pinto Slottow TL; Roy PK; Okabe T; Bonello L; de Labriolle A; Smith KA; Torguson R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
Am J Cardiol; 2008 Jul; 102(2):160-4. PubMed ID: 18602514
[TBL] [Abstract][Full Text] [Related]
19. Comparison of anti-thrombotic strategies using Bivalirudin, Heparin plus Glycoprotein IIb/IIIa inhibitors and Unfractionated Heparin Monotherapy for patients undergoing percutaneous coronary intervention - A single centre observational study.
Kaul U; Dua A; Sethi AK; Arambam P; Seth A
Indian Heart J; 2015; 67(4):311-7. PubMed ID: 26304562
[TBL] [Abstract][Full Text] [Related]
20. Sex-based differences in outcomes with bivalirudin or unfractionated heparin for transcatheter aortic valve replacement: Results from the BRAVO-3 randomized trial.
Asgar A; Chandrasekhar J; Mikhail G; Webb J; Lefèvre T; Tamburino C; Hildick-Smith D; Hambrecht R; Van Belle E; Widder J; Dumonteil N; Hink U; Jeger R; Linke A; Deliargyris E; Gao P; Mehran R; Hengstenberg C; Anthopoulos P; Dangas G;
Catheter Cardiovasc Interv; 2017 Jan; 89(1):144-153. PubMed ID: 27152677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
